Company Overview of Capsugel Inc.
Capsugel Inc. develops dosage forms and solutions for the healthcare industry around the world. It offers gelatin, alternate polymer, and liquid-filled capsules; hard gelatin, sprinkle, plus HPMC, fish gelatin, pearlescent, over-encapsulation, pre-clinical, liquid, soft gelatin, acid-resistant capsules; gelcaps; capsule in capsule technology products; and solid lipid pellet technology products. The company also provides precision powder micro-dosing systems, CFS liquid filling and sealing machines, profill manual capsule filling machines, and commercial scale capsule filling machines. The company develops drug delivery technology platform, enTRinsic, that offers enteric protection without th...
412 Mount Kemble Avenue
Morristown, NJ 07960
Founded in 1963
Key Executives for Capsugel Inc.
Chief Executive Officer and President
Chief Marketing Officer and Senior Vice President
Senior Vice President of Research and Development
Senior Director of Corporate Communications
Compensation as of Fiscal Year 2015.
Capsugel Inc. Key Developments
Capsugel Introduces enTRinsic Drug Delivery Technology Platform
Oct 26 15
Capsugel has launched its enTRinsic drug delivery technology platform, which offers enteric protection without the requirement of functional coatings. The technology provides targeted release of gastric acid- and heat-sensitive active ingredients to the upper gastrointestinal tract. It allows oral delivery of several compounds, including vaccines, proteins and peptides, using pharmaceutically approved enteric polymers. The technology is now available worldwide for customer projects after the completion of a lead-user customer-collaboration program, which was undertaken in 18 months. The enTRinsic technology further expands Capsugel's range of modified and targeted release solutions, and the company's biotherapeutic formulation offering.
Capsugel and Cardax to Collaborate on Development of Proprietary Astaxanthin Products
Aug 19 14
Capsugel and Cardax, Inc. announced a collaboration to develop unique astaxanthin products for the consumer health market. The goal of the collaboration is to commercialize proprietary formulations of nature-identical synthetic astaxanthin products with pharmaceutical-grade purity that will provide improved oral bioavailability compared with other astaxanthin products on the market. Astaxanthin is currently used as a specialized antioxidant. The astaxanthin products will be jointly developed using Capsugel's proprietary lipid multi-particulate (LMP) technology, which encapsulates dissolved or suspended active ingredients into spherical lipid matrix particles for oral dosage in capsules, sachets, suspensions or tablets. LMP technology utilizes a range of approved lipids to deliver the benefits of lipid-based formulations in multi-particulate format, including improved bioavailability, controlled release and effective taste-masking. The companies will seek a strategic partner for retail commercialization in the mass market. Specific business terms were not disclosed.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries